Atossa Therapeutics staples CVRs to ATOS shares tied to priority review voucher proceeds

• Atossa Therapeutics executed a stapled contingent value rights agreement, attaching one CVR to each common share.
• CVRs remain stapled unless the board elects to detach them, allowing transfers only together with the related shares.
• Coverage applies to shares outstanding on Oct. 19, 2026 record date, including shares issued before detachment or expiry.
• CVRs give holders 25% of net proceeds from the first qualifying FDA priority review voucher monetization, capped at USD 50 million.
• Eligibility limited to the first qualifying voucher awarded on or before Dec. 31, 2036, subject to board extension.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF66627) on October 09, 2026, and is solely responsible for the information contained therein.